Cadwalader allows sharing content.
Email to a friend or colleague:
From
To
Subject
Email Salix, a leading U.S. specialty pharmaceutical company, agreed to be acquired by Valeant for $158.00 per share, or a total enterprise value of approximately $14.5 billion. https://www.cadwalader.com/news/news-release/cadwalader-represents-salix-pharmaceuticals-in-its-pending-acquisition-by-valeant-pharmaceuticals